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Abstract
Background: Estrogen deficiency increases the cardiovascular risks in postmenopausal women. Inhibition of the renin-
angiotensin system (RAS) and associated oxidative stress confers a cardiovascular protection, but the role of RAS in estrogen
deficiency-related vascular dysfunction is unclear. The present study investigates whether the up-regulation of RAS and
associated oxidative stress contributes to the development of endothelial dysfunction during estrogen deficiency in
ovariectomized (OVX) rats.
Methodology/Principal Findings: Adult female rats were ovariectomized with and without chronic treatment with
valsartan and enalapril. Isometric force measurement was performed in isolated aortae. The expression of RAS components
was determined by immunohistochemistry and Western blotting method while ROS accumulation in the vascular wall was
evaluated by dihydroethidium fluorescence. Ovariectomy increased the expression of angiotensin-converting enzyme (ACE),
angiotensin II type 1 receptor (AT1R), NAD(P)H oxidase, and nitrotyrosine in the rat aorta. An over-production of angiotensin
II and ROS was accompanied by decreased phosphorylation of eNOS at Ser
1177 in OVX rat aortae. These pathophysiological
changes were closely coupled with increased oxidative stress and decreased nitric oxide bioavailability, culminating in
markedly impaired endothelium-dependent relaxations. Furthermore, endothelial dysfunction and increased oxidative
stress in aortae of OVX rats were inhibited or reversed by chronic RAS inhibition with enalapril or valsartan.
Conclusions/Significance: The novel findings highlight a significant therapeutic benefit of RAS blockade in the treatment of
endothelial dysfunction-related vascular complications in postmenopausal states.
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Introduction
Menopause is a risk factor for cardiovascular diseases as
estrogen deficiency is known to impair cardiovascular function
and metabolism [1]. Loss of estrogen-dependent cardiovascular
protection diminishes endothelial function, and may involve
activation of the renin-angiotensin system (RAS). Clinical and
animal studies indicate an inverse association between estrogen
and the RAS activation [2,3,4,5,6]. Endothelial dysfunction
caused by reduced bioavailability of nitric oxide (NO) and/or
elevated formation of reactive oxygen species (ROS) in the
vascular wall, sets into motion in a sequence of events leading to
the development of cardiovascular complications [7,8]. Endothe-
lial dysfunction occurs during estrogen deficiency [9,10] and
estrogen improves endothelial function in postmenopausal women
[11]. Ample evidences suggest a critical involvement of the RAS in
the initiation of endothelial dysfunction [12,13]. Angiotensin II
elicits several harmful effects on vascular wall through angiotensin
type 1 receptor (AT1R) including vasoconstriction, vascular
smooth muscle cell (VSMC) proliferation, ROS generation, and
endothelial cell apoptosis [14,15,16]. Cardiovascular protection
can thus be achieved by either inhibiting the synthesis of
angiotensin II or by blocking the binding of angiotensin II to
AT1R.
Hypertension and osteoporosis are the two important age-
related disorders in postmenopausal women. Angiotensin II
infusion accelerates osteoporosis in ovariectomized (OVX) rats
[17]. Although there is some concern that use of AT1R blockers
could exacerbate postmenopausal osteoporosis, a recent animal
study did not confirm this as chronic treatment of OVX rats with
valsartan did not accelerate OVX-induced bone loss [18]. Instead,
treatment of hypertensive mice with an ACE inhibitor reduces
osteroporosis and hypertension [19]. Thus, blockade of angioten-
sin II may be an effective therapeutic approach to prevent
osteoporosis and treat hypertension in postmenopausal women
usually afflicted by both age-related conditions. Limited clinical
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17437data also shows that AT1R blockers improve endothelial
dysfunction after menopause and treatment with candesartan
lowers blood pressure [20] and ameliorates endothelial dysfunction
[21] in postmenopausal women.
Despite reported therapeutic benefit of RAS inhibition in
hypertension, the precise role of the activation of the RAS-
oxidative stress axis in the induction and maintenance of
endothelial dysfunction in the estrogen-deficient state remains
unclear. Therefore, the present study investigates the hypothesis
that the activation of the RAS and associated oxidative stress
mediate endothelial dysfunction during estrogen deficiency and
chronic treatment with enalapril (ACE inhibitor) or valsartan
(AT1R blocker) could restore the impaired endothelial function in
estrogen-deficient OVX rats, an animal model widely employed to
mimic menopause.
Results
Basic parameters
Rats had an increased body weight 12 weeks after OVX and
this gain was unaltered by enalapril or valsartan. The reduced
uterine weight and serum oestradiol level in OVX rats were
unaffected by chronic RAS blockade (Table 1). OVX caused a
small but insignificant increase in blood pressure compared with
sham-operated rats (p.0.05). Chronic treatment with enalapril or
valsartan slightly lowered blood pressure, but did not affect OVX-
induced increase in heart weight or decrease in the uterine weight
and estrogen level (Table 1). The ratio of heart weight over body
weight was comparable in the four treatment groups (Table 1).
OVX elevated plasma levels of total cholesterol, triglyceride, HDL
and non-HDL, while valsartan or enalapril treatment produced
varied effects on these parameters (Table 1).
Ovariectomy inhibits endothelium (NO)-dependent but
not -independent relaxations
Acetylcholine-induced endothelium-dependent relaxations were
impaired progressively following OVX with time-dependent
reductions in the maximum response (Figure 1A, Table 2). By
contrast, SNP-induced endothelium-independent relaxations were
similar at different time points after OVX (Figure 1B), indicating
that the sensitivity of aortic smooth muscle cells in response to NO
was unaltered in estrogen-deficient rats.
AT1R inhibitor and ROS scavengers acutely ameliorate
OVX-related endothelial dysfunction
The impaired endothelial NO-mediated relaxations in OVX
rats were reversed acutely by 30-min treatment with losartan
(Figure 2A). Acute exposure to apocynin also restored the
impaired relaxations (Figure 2B). A combined treatment with
losartan and apocynin did not result in additional improvement of
the relaxations (Figure 2C). The important role of ROS in the
impaired endothelial function was further supported by a complete
restoration of relaxations by ROS scavengers, tiron plus DETCA
(Figure 2D). The ACh-induced relaxations under pharmacological
treatments were abolished by 100 mmol/l N
G-nitro-L-arginine
methyl ester (L-NAME) (data not shown).
Chronic RAS blockade prevents endothelial dysfunction
Chronic treatment of OVX rats with enalapril (Figure 3A) or
valsartan (Figure 3B) reversed the impaired acetylcholine-induced
relaxations. Chronic treatment with valsartan (but not enalapril)
restored the phosphorylation of eNOS at ser
1177 in the presence of
acetylcholine, which was reduced in OVX rat aortae, while total
eNOS expressions were not altered among all the groups
(Figure 3E). The improved relaxations in enalapril-treated OVX
rats was unaffected by 30-min treatment with 100 nmol/l HOE-
140, a bradykinin type-2 receptor antagonist (Figure 3C). In
addition, acute treatment with the ACE inhibitor captopril did not
improve the impaired relaxation in OVX rat aortae (Figure 3D),
suggesting that acute ACE inhibition in isolated aortas from OVX
rats can not reduce the downstream ROS production.
ACE expression and angiotensin II levels in the vascular
wall
ACE expressions were significantly higher in aortae of OVX
rats than those of sham-operated rats as revealed by immunoblot-
ting (Figure 4A) and immunohistochemistry (Figure 4B). The
Table 1. Basic Parameters.
Control OVX OVX + Ena OVX + Val
Basic Parameters
Body weight (BW) (g) 237.564.8 351.766.0
a,*** 337.064.9 345.068.5
Systolic blood pressure (mmHg) 101.062.9 105.962.0 97.961.4
b,** 99.661.8
b,*
Heart weight (HW) (g) 0.9560.01 1.3560.01
a,** 1.2860.01 1.2960.04
Uterus weight (g) 0.4960.06 0.0960.01
a,*** 0.0760.01 0.0760.01
HW/BW (%) 0.4060.005 0.3860.025 0.3860.008 0.3660.012
Plasma biomarkers
Plasma estrogen (pg/ml) 21.761.11 5.6360.35
a,*** 6.4860.28 5.6760.53
Total cholesterol (mg/dl) 85.861.9 122.061.6
a,*** 123.262.0 138.663.1
b,***
Triglyceride (mg/dl) 81.860.4 112.462.2
a,*** 100.365.9 106.062.0
HDL (mg/dl) 51.260.8 60.160.5
a,*** 77.462.2
b,*** 72.161.0
b,***
Non-HDL (mg/dl) 34.762.2 61.961.7
a,*** 45.862.7
b,*** 66.263.8
Non-HDL/HDL ratio 0.6860.05 1.0360.03
a,*** 0.9260.06 0.6060.05
b,***
Basic parameters measured in control, OVX rat with and without chronic treatment with enalapril (OVX+Ena) or valsartan (OVX+Val) include body weight, blood
pressure, heart weight and uterine weight. Plasma parameters include oestrogen and various lipids. Results are means6SEM of six animals. Statistical significance
between (a) control versus OVX and (b) OVX versus treatment is indicated by * p,0.05, ** p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0017437.t001
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enalapril or valsartan (Figure 4A&B). Immunohistochemical
staining showed an increased number of angiotensin II-positive
cells in the vascular wall of the OVX rat aortas (Figure 4C).
Chronic treatment with enalapril but not valsartan reduced the
increased staining of angiotensin II (Figure 4C).
AT1R and AT2R expression
The protein levels of AT1R were markedly elevated in aortae of
OVX rats. Chronic treatment with valsartan but not enalapril
reduced the up-regulation of AT1R expression (Figure 5A). By
contrast, the protein expression for AT2R was unaltered by OVX
or by drug treatment (Figure 5A). Angiotensin II (100 nmol/l)
produced a greater contraction in OVX rat aortae and this
augmented contraction was inhibited by chronic treatment with
valsartan but not enalapril (Figure 5B). By contrast, 60 mmol/l
KCl produced a comparable aortic contraction in different groups
(Figure 5C).
NAD(P)H oxidase expression and ROS production
Ovariectomy increased the expression of NAD(P)H oxidase
subunits, gp91
phox and p22
phox in rat aortae, which was significantly
inhibited in enalapril- or valsartan-treated OVX rats (Figure 6A).
DHE fluorescence revealed an elevated ROS production in the
vascular wall in the OVX rat aorta and this increase was
attenuated by enalapril and prevented by valsartan treatment
(Figure 6B). Likewise, the upregulation of nitrotyrosine, a marker
of oxidative stress, in OVX rat aortae was largely inhibited by
chronic treatment with both enalapril and valsartan (Figure 6C).
Discussion
The present study reveals a principal role of the RAS activation
and resulting oxidative stress in the induction of endothelial
dysfunction in estrogen-deficient OVX rats. Endothelial dysfunc-
tion is caused by perturbation of the balance between NO and
ROS. Ovariectomy leads to reduced NO bioavailability which
accounts for the impaired endothelium-dependent relaxations
during estrogen deficiency through a cluster of inter-connected
cellular events in the vascular wall: (i) increased expression of
ACE, (ii) augmented production of angiotensin II leading to over-
expression of AT1R, (iii) greater production of ROS due to
increased expression and activity of NAD(P)H oxidase, and (iv) the
increased content of nitrotyrosine, a footprint for increased
formation of peroxynitrite from NO and O2
2. An important role
for RAS activation in endothelial dysfunction was confirmed in
OVX rats that were treated with valsartan and enalapril, widely
used in the treatment of hypertension.
ROS are important contributors to endothelial dysfunction and
subsequent development of vascular events. Increased ROS
negates the vascular benefit of NO [22]. The present study shows
that acute treatment with apocynin [a putative NAD(P)H oxidase
inhibitor] markedly improves acetylcholine-induced relaxations of
OVX rat aortae, suggesting a significant involvement of this
oxidase in endothelial dysfunction. Furthermore, estrogen defi-
ciency results in the increased expression of membrane-bound
NAD(P)H oxidase submits, gp91
phox and p22
phox. The essential role
of ROS is further supported by the observations that ROS
scavengers, tiron plus DETCA, normalizes the impaired relaxa-
tions of OVX rat aortae. The present study also showed that the
increased level of AT1R and augmented angiotensin II-induced
vasoconstriction in the presence of L-NAME after ovariectomy
Figure 1. Ovariectomy impairs endothelium-dependent relaxation. Time-dependent reduction of endothelium-dependent relaxations
induced by acetylcholine (ACh, A) but not by sodium nitroprusside (SNP, B) in phenylephrine (Phe)-contracted ring with endothelium following
ovariectomy. Results are means6SEM of 6–8 experiments. Statistical significance between control and OVX curves is indicated by *** p,0.001.
doi:10.1371/journal.pone.0017437.g001
Table 2. pD2 and Emax (%) for acetylcholine-induced
relaxations.
Initial tone (g) pD2 Emax (%) n
Control (12 wks) 0.6060.03 7.396.07 92.761.9 6
OVX (4 wks) 0.9260.07
a,** 6.6060.10
a,*** 93.162.9 6
OVX (8 wks) 0.9360.11
a,** 7.0260.10
a,* 76.763.0
a,** 6
OVX (12 wks) 1.0060.06
a,*** 7.0460.18
a,* 55.063.5
a,*** 8
Acute treatment
OVX (12 wks) 1.0060.06 7.0460.18 55.061.9 8
+Losartan (Los) 1.1060.04 7.2060.10 84.362.7
b,*** 6
+Apocynin (Apo) 0.9360.20 7.1760.13 86.763.3
b,*** 6
+Los+Apo 0.9560.16 7.1160.08 89.562.3
b,*** 6
+Tiron+DETCA 0.9060.18 7.2660.07 90.161.9
b,*** 6
Chronic treatment
Control 0.6560.12 7.3760.07 89.061.9 6
OVX 1.1260.09
a,** 6.8860.11
a,* 50.162.2
a,*** 8
OVX+Enalapril 0.8160.08
b,* 7.2360.12 79.463.2
b,*** 8
OVX+Valsartan 1.0760.06 7.1560.10
b,* 83.662.8
b,*** 8
Initial tension developed by phenylephrine, pD2 and Emax (%) for acetylcholine-
induced relaxations in aortae from different groups. Results are means6SEM of
6–8 experiments. Statistical significance between (
a) control versus OVX and (
b)
OVX versus acute or chronic treatment is indicated by *p,0.05, **p,0.01, and
***p,0.001.
doi:10.1371/journal.pone.0017437.t002
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valsartan but not enalapril treatment. Angiotensin II stimulation of
AT1R on the vascular wall is known to activate NAD(P)H oxidase
[23,24] and pathological roles of NAD(P)H oxidase are reported in
hypertensive rats [13,14]. In the present study, chronic RAS
blockade blunts the increased expression of NAD(P)H oxidase in
OVX rat aortae and this effect may be directly linked to the
vascular benefit of RAS blockers. Increased oxidative stress in
OVX rat aortae is further supported by elevated levels of
nitrotyrosine, an oxidative stress biomarker. Staining intracellular
ROS with DHE confirms over-production of O2
2 in the vascular
wall. Increases in both nitrotyrosine and ROS are inhibited or
prevented by chronic RAS blockade. In addition, combined
treatment with losartan and apocynin does not produce additional
improvement in acetylcholine-induced relaxations, suggesting that
both agents are equi-effective in reducing oxidative stress. Taken
in conjuncture, AT1R-associated activation of NAD(P)H oxidase is
the major stimulus for the over-production of ROS in OVX rat
aortae and thus plays a key role in causing endothelial dysfunction
during estrogen deficiency.
We next attempt to identify the possible triggering signal
involved in increased oxidative stress during estrogen deficiency.
Ovariectomy results in the increased expression of ACE in aortae,
an effect that was not reported before. The increased levels of
ACE would expectedly lead to an augmented production of
angiotensin II. Indeed, higher levels of angiotensin II-positive cells
in the vascular wall can be localized using immunohistochemical
staining in OVX rat aortae. Chronic treatment with enalapril
reverses the increased levels of ACE and angiotensin II to those in
sham-operated rat aortae. Thus, the increased availability of
angiotensin II likely accounts for the increased expression and
activity of NAD(P)H oxidase that culminates in endothelial
dysfunction. Previously studies reported that angiotensin II
increased the protein levels of AT1R, NAD(P)H oxidase, and
nitrotyrosine in cultured porcine endothelial cells [25] and that
oxidative stress reduced the NO bioavailability in angiotensin
II-infused mammals [26]. The present findings suggest a
therapeutic potential of RAS inhibition in amelioration of
oxidative stress-related endothelial dysfunction in states of estrogen
deficiency.
ACE is also known to cleave bradykinin into biologically
inactive smaller fragments and ACE inhibition preserves plasma
bradykinin, a vasodilator in postmenopausal women [27]. If
bradykinin contributes to the improved endothelial function, the
augmented relaxations in enalapril-treated OVX rats would be
blunted by bradykinin receptor blockade. Acute treatment with
HOE-140, however, fails to produce such effects, suggesting that
enalapril-induced endothelial cell protection is mediated primarily
through inhibition of the synthesis of angiotensin II, rather than a
decreased degradation of bradykinin in the vascular wall.
Furthermore, bradykinin fails to relax rat aortae (data not shown),
thus ruling out an involvement of bradykinin.
The present study provides novel evidence for complex
mechanisms involved in the vascular benefit of valsartan.
Analogous to the inhibitory effect of enalapril on the RAS-
oxidative stress axis, valsartan exerts several previously un-
reported benefits: (i) increasing the phosphorylation of eNOS at
Ser
1177 responsible for improved endothelial function, (ii) prevent-
ing the increased expression of ACE and thus reducing the over-
production of angiotensin II, and (iii) reducing over-expression for
AT1R. An elevated AT1R expression within the vascular wall of
OVX rat aortae may be related to a loss of circulating estrogen as
estrogen inhibits the basal expression and function of AT1Ri n
cultured rat aortic vascular smooth muscle [4].
In the vascular wall, AT1R activation leads to unfavorable
cellular responses including oxidative stress, lipid peroxidation,
NO inactivation, and activation of redox-sensitive genes, which
collectively participate in the initiation of vascular dysfunction
[14,22,28]. The present study is probably the first to report that
chronic valsartan treatment increases the NO bioavailability by
increasing eNOS phosphorylation. Previous animal and human
studies with AT1R blockers, however, did not determine the
Figure 2. AT1R inhibitor and ROS scavengers acutely ameliorate OVX-related endothelial dysfunction. Inhibitory effects of 30-min
treatment with 3 mmol/l losartan (A), 100 mmol/l apocynin (B), 3 mmol/l losartan plus 100 mmol/l apocynin (C), and 1 mmol/l tiron plus 100 mmol/l
DETCA (D) on ACh-induced relaxations. Results are means6SEM of 6–8 experiments. Statistical significance between OVX and drug-treated OVX is
indicated by *** p,0.001.
doi:10.1371/journal.pone.0017437.g002
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AT1R leads to the elevated expression and activity of NAD(P)H
oxidase; subsequent over-production of ROS lowers the NO
bioavailability and hence impairs endothelium-dependent relaxa-
tions. Reduced eNOS activity resulting from a loss of circulating
estrogen [31] impairs endothelial function. However, it is yet to be
determined whether there exists a difference in the long-term
impact between early and late ovariectomy on vascular function
due to possible difference in the duration of prior hormonal
exposure in rats. This possibility deserves further examination.
Treatment with valsartan or enalapril increased the plasma HDL
level in OVX rats. In addition, valsartan treatment also lowered
the non-HDL/HDL ratio in OVX rats and this may also benefit
vascular function in vivo.
In summary, the present study elucidates a critical role of the
RAS activation and associated oxidative stress in the induction
and maintenance of endothelial dysfunction during estrogen
deficiency. Treatment with enalapril (ACE inhibitor) or valsartan
(AT1R blocker) restores endothelial function in OVX female rats.
The novel findings provide mechanistic support for the limited
clinical observations that RAS blockade may protect against
cardiovascular diseases in postmenopausal women. Either ACE
inhibitors or AT1R blockers could be an effective alternative to
estrogen replacement or raloxifene therapy for menopausal
women.
Materials and Methods
Drug treatment
This investigation conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institute of
Health (NIH Publication No. 85-23, revised 1996), and approved
Figure 3. Chronic RAS blockade prevents endothelial dysfunction. Concentration-response curves for ACh in aortae from control, OVX rats
and OVX rats treated with enalapril (A, OVX+Ena) or valsartan (B, OVX+Val). (C) Lack of effect of HOE-140 on relaxations in aortae from OVX+Ena
group. (D) Lack of effect of captopril on relaxations in OVX rats. (E) Phosphorylated levels of eNOS (p-eNOS) at Ser
1177 in response to 1 mmol/l ACh
and the total eNOS in aortae. Results are means6SEM of 6–8 experiments. Intensities were normalized to GAP(D)H and expressed relative to control.
Statistical significance between OVX and treatment group is indicated by *** p,0.001. NS, no significance.
doi:10.1371/journal.pone.0017437.g003
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University of Hong Kong (4362/04 M). Adult female Sprague-
Dawley rats (three-month old weighing 200–230 g) were
supplied by the Animal Service Center of Chinese University
of Hong Kong and housed under a 12-h light/dark cycle and fed
ad libitum. Ovariectomy was performed via a mid-abdominal
route after rats were anesthetized using sodium pentobarbital
(40 mg kg
21 body weight via intraperitoneal injection) [10].
Four groups (6–8 rats in each) were included: (1) OVX rats
receiving vehicle (OVX); (2) OVX rats receiving daily oral
administration of 10 mg kg
21 enalapril (OVX+Ena) for eight
weeks; (3) OVX+Val, OVX rats receiving daily oral adminis-
tration of 10 mg kg
21 valsartan (OVX+Val) for eight weeks; and
(4) sham-operated rats. The initial results showed that acetyl-
choline-induced relaxations were impaired starting at four weeks
after ovariectomy and were maximally reduced (by 40%) twelve
weeks after ovariectomy. Therefore, drug treatment was initiated
at the 4
th week after surgery and lasted for the following eight
weeks.
At the end of drug treatment, blood was drawn from the heart,
collected in heparin-containing BD VacutainerH while plasma was
collected after centrifugation and stored frozen at 220uC until
further bioassay. The concentration of plasma oestrogen was
measured using immunosorbent assay kit (Cayman, Ann Arbor,
MI, USA). After aortae were removed, the heart and uterus were
dissected free of surrounding fat pads and weighed.
Blood vessel preparation
The thoracic aorta was dissected and cleaned of adhering
connective tissue in an ice-cold and oxygenated Krebs solution
containing (mmol/l): 119 NaCl, 4.7 KCl, 2.5 CaCl2, 1 MgCl2,2 5
NaHCO3, 1.2 KH2PO4, and 11 D-glucose. Each aorta was cut
into several ring segments (,3 mm long) for parallel studies. Each
ring was suspended between two stainless steel hooks in a 10-ml
organ bath filled with Krebs solution, which was bubbled with
95% O2 plus 5% CO2 and maintained at 37uC (pH: ,7.4). One
hook was fixed to the bottom of the bath while the other was
connected to a Grass force displacement transducer. An optimal
baseline tone of 2 g was applied to all rings. In some aortae, the
endothelial layer was mechanically disrupted and functional
removal of endothelium was verified by the lack of relaxation
to 1 mmol/l acetylcholine. High KCl-containing solution was
Figure 4. Chronic RAS blockade reduces ACE expression and angiotensin II levels after ovariectomy. Effects of chronic treatment of OVX
rats with enalapril or valsartan on the protein level of angiotensin-converting enzyme (ACE) revealed by Western blot (A) and immunohistochemistry
(B). Immunohistochemical staining of angiotensin II in the aortic vascular wall (C). Sections are counterstained with hematoxylin. Magnification6400.
Results are means6SEM of 4–6 experiments. Statistical significance is indicated by ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0017437.g004
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to retain a constant ionic strength.
Isometric tension measurement
Thirty minutes after setting up in organ bath, each ring was first
contracted with 1 mmol/l phenylephrine and then relaxed by
1 mmol/l acetylcholine to test smooth muscle contractility and the
integrity of the endothelium. Rings were then rinsed in pre-warmed
Krebs solution until baseline tension returned. Two consecutive
concentration-response curves to acetylcholine (3 nmol/l–10 mmol/
l) were studied in control and in the presence (30-min incubation) of
one of the following inhibitors: losartan (3 mmol/l), apocynin
(100 mmol/l), tiron (1 mmol/l) plus diethyldithiocarbamate acid
(DETCA, 100 mmol/l), and captopril (100 mmol/l). Acetylcholine-
induced relaxations were compared in different treatment groups.
Endothelium-independent relaxationstosodiumnitroprusside (SNP)
were also examined. Finally, a single concentration of angiotensin II
(100 nmol/l) was used to trigger transient contraction in the
presence of 100 mmol/L L-NAME because the aortae developed a
rapid desensitization to consecutive application of angiotensin II.
The contraction in response to 60 mmol/l KCl-containing Krebs
solution was also performed and compared in aortae from different
groups.
Western blotting
Aortae were snap frozen in liquid nitrogen and homogenized in
an ice-cold RIPA lysis buffer. The lysates were centrifuged and the
supernatant was collected. The protein concentration was
determined. Protein samples (50 mg) were separated with 10%
SDS-polyacrylamide gel and then transferred to a nitrocellulose
immobilon-P polyvinylidene difluoride membrane. The mem-
branes were blocked with 1% bovine serum albumin. Primary
antibodies against eNOS (1:500, BD Transduction Laboratories,
KY, USA), eNOS phosphorylated at ser
1177 (1:1000, Upstate
Biotechnology, Lake Placid, NY), ACE (1:1000, Santa Cruz, CA,
USA), AT1R (1:1000, Abcam, MA, USA), AT2R (1:1000, Abcam,
MA, USA), gp91
phox (1:500, Santa Cruz, CA, USA), p22
phox (1:500,
Santa Cruz, CA, USA), nitrotyrosine (1:1000, Upstate Biotech-
nology, NY, USA), and GAPDH (1:3000, Ambion, TX, USA)
were used. Corresponding secondary antibody conjugated to
horseradish peroxidase (DakoCytomation) were used. The mem-
branes were developed with an enhanced chemiluminescence
Figure 5. Chronic RAS blockade decreases AT1R expression. (A) Effects of chronic treatment with enalapril or valsartan on protein levels of
angiotensin II type 1 (AT1R) and type 2 receptor (AT2R) in aortae of OVX rats. Aortic contraction induced by 100 nmol/l angiotensin II (B) and
60 mmol/l KCl (C) in the presence of 100 mmol/l L-NAME. Results are means6SEM of 4–5 experiments. Statistical significance is indicated by * p,0.05
and *** p,0.001.
doi:10.1371/journal.pone.0017437.g005
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performed using a documentation programme.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
sections of aortic rings. Angiotensin II in the vascular wall was
stained by rabbit polyclonal anti-angiotensin II antibody (1:500
dilution in normal goat serum; Peninsula laboratory, CA, USA);
and ACE by goat polyclonal anti-ACE antibody (1:200 dilution in
normal donkey serum; Santa Cruz, CA, USA), followed by
secondary antibody conjugated with biotin (Jackson Immunor-
esearch, West Grove, PA, USA). Immunopositive signals were
detected with streptavidin-HRP (Zymed, San Francisco, CA,
USA), visualized with DAB (Vector laboratory, Burlingame, CA,
USA), and counterstained with hematoxylin. The nonspecific
binding was controlled by substitution of the primary antibody for
negative comparison. Images were obtained under a light micro-
scopy, and analyzed by ImageJ (NIH).
ROS detection by dihydroethidium (DHE) fluorescence
Intracellular oxidants in aortic rings were measured using
dihydroethidium (DHE; Molecular Probes, Eugene, OR, USA),
which binds to DNA when oxidized to emit fluorescence.
Frozen sections were cut in 15-mm thickness, and incubated at
37uC for 30 min in 5 mmol/l DHE. Fluorescence was observed
under a confocal microscope (515-nm excitation; 585-nm long
pass filter; Olympus Fluoview). DHE fluorescence intensity was
analyzed by Fluoview (version 1.5; FV10-ASW1.5). For each
section, a square region with an area of 80 mm680 mmw a s
selected for analysis. The summarized data represents the fold
change in fluorescence intensity relative to that in control rat
aortae.
Figure 6. Chronic RAS blockade decreases oxidative stress. Effects of chronic treatment with enalapril or valsartan on the protein expression
of NAD(P)H oxidase subunits: gp91
phox and p22
phox (A), on ROS production as revealed by DHE fluorescent intensity (B), and on the protein level of
nitrotyrosine (C) in rat aortae. Results are means6SEM of 4–5 experiments. Statistical significance is indicated by ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0017437.g006
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Phenylephrine, acetylcholine, sodium nitroprusside, captopril,
apocynin, tiron, DETCA, N
G-nitro-L-arginine methyl ester were
from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Losartan was
purchased from Cayman Chemical (Ann Arbor, MI, USA).
Apocynin and losartan were dissolved in dimethyl sulfoxide
(DMSO) and others in distilled water. DMSO at 0.1% (v/v) did
not affect acetylcholine-induced relaxations.
Statistical analysis
Results represent means6SEM from n different rats. The
concentration-response relationship was analyzed with a non-
linear curve fitting (GraphPad Prism, Version 4.0). The pD2 was
calculated as the negative logarithm of the dilator concentration
that produced 50% of the maximum relaxation (Emax). The
protein expression was normalized to GAPDH and then expressed
relative to the control. Student’s t-test (unpaired two-tailed) was
used and concentration-response curves were analyzed by two-way
ANOVA followed by Bonferroni post-hoc tests. P,0.05 indicates
significant difference.
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